Relationship of carnitine and carnitine precursors lysine, ε-N-trimethyllysine, and γ-butyrobetaine in drug-induced carnitine depletion

B. Melegh, Maria Pap, Ildiko Bock, Charles J. Rebouche

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Plasma concentrations and rates of urinary excretion of carnitine and some of its precursors were studied in three groups of children receiving drugs known to cause carnitine depletion. Patients in group A received pivampicillin and a molar equivalent of carnitine for 7 d. Patients in group B received pivampicillin with a 5.8-fold molar excess of carnitine for 1 wk. Patients in group C were treated chronically with valproic acid and received a molar equivalent (to valproic acid) of carnitine for 14 d. Patients in group A had markedly increased (16-fold) urinary carnitine ester excretion concomitant with diminished urinary free carnitine and γ-butyrobetaine output and lower plasma free carnitine concentration. Supplementation with one molar equivalent of carnitine (to pivampicillin) was ineffective in preventing the reduction of plasma carnitine concentration observed with pivampicillin treatment alone. For group B patients, administration of excess carnitine resulted in a further increase (35-fold) of urinary carnitine ester output with no decrease of plasma carnitine concentration, urinary γ-butyrobetaine, or free carnitine excretion. For patients in group C, the initially low plasma free and total carnitine concentrations and urinary output of carnitine and carnitine esters markedly increased with carnitine supplementation, but urinary excretion of γ-butyrobetaine remained unchanged. The plasma concentrations and urinary output of L-lysine and ε-N-trimethyllysine remained unchanged within each group before and after treatment. A positive linear correlation was found between urinary ε-N-trimethyllysine and 3-methylhistidine output, indicating that the rate of ε-N-trimethyllysine excretion correlates with the amount of 3-methylhistidine liberated by protein turnover. The data indicate that generation of ε-N-trimethyllysine probably depends on protein breakdown but its use for carnitine synthesis is not necessarily regulated by carnitine status.

Original languageEnglish
Pages (from-to)460-464
Number of pages5
JournalPediatric Research
Volume34
Issue number4
Publication statusPublished - 1993

Fingerprint

Carnitine
Lysine
Pharmaceutical Preparations
Pivampicillin
gamma-butyrobetaine
trimethyllysine
Esters
Valproic Acid

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Relationship of carnitine and carnitine precursors lysine, ε-N-trimethyllysine, and γ-butyrobetaine in drug-induced carnitine depletion. / Melegh, B.; Pap, Maria; Bock, Ildiko; Rebouche, Charles J.

In: Pediatric Research, Vol. 34, No. 4, 1993, p. 460-464.

Research output: Contribution to journalArticle

@article{b103efe156c54f3e9c9486d85d01d45b,
title = "Relationship of carnitine and carnitine precursors lysine, ε-N-trimethyllysine, and γ-butyrobetaine in drug-induced carnitine depletion",
abstract = "Plasma concentrations and rates of urinary excretion of carnitine and some of its precursors were studied in three groups of children receiving drugs known to cause carnitine depletion. Patients in group A received pivampicillin and a molar equivalent of carnitine for 7 d. Patients in group B received pivampicillin with a 5.8-fold molar excess of carnitine for 1 wk. Patients in group C were treated chronically with valproic acid and received a molar equivalent (to valproic acid) of carnitine for 14 d. Patients in group A had markedly increased (16-fold) urinary carnitine ester excretion concomitant with diminished urinary free carnitine and γ-butyrobetaine output and lower plasma free carnitine concentration. Supplementation with one molar equivalent of carnitine (to pivampicillin) was ineffective in preventing the reduction of plasma carnitine concentration observed with pivampicillin treatment alone. For group B patients, administration of excess carnitine resulted in a further increase (35-fold) of urinary carnitine ester output with no decrease of plasma carnitine concentration, urinary γ-butyrobetaine, or free carnitine excretion. For patients in group C, the initially low plasma free and total carnitine concentrations and urinary output of carnitine and carnitine esters markedly increased with carnitine supplementation, but urinary excretion of γ-butyrobetaine remained unchanged. The plasma concentrations and urinary output of L-lysine and ε-N-trimethyllysine remained unchanged within each group before and after treatment. A positive linear correlation was found between urinary ε-N-trimethyllysine and 3-methylhistidine output, indicating that the rate of ε-N-trimethyllysine excretion correlates with the amount of 3-methylhistidine liberated by protein turnover. The data indicate that generation of ε-N-trimethyllysine probably depends on protein breakdown but its use for carnitine synthesis is not necessarily regulated by carnitine status.",
author = "B. Melegh and Maria Pap and Ildiko Bock and Rebouche, {Charles J.}",
year = "1993",
language = "English",
volume = "34",
pages = "460--464",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Relationship of carnitine and carnitine precursors lysine, ε-N-trimethyllysine, and γ-butyrobetaine in drug-induced carnitine depletion

AU - Melegh, B.

AU - Pap, Maria

AU - Bock, Ildiko

AU - Rebouche, Charles J.

PY - 1993

Y1 - 1993

N2 - Plasma concentrations and rates of urinary excretion of carnitine and some of its precursors were studied in three groups of children receiving drugs known to cause carnitine depletion. Patients in group A received pivampicillin and a molar equivalent of carnitine for 7 d. Patients in group B received pivampicillin with a 5.8-fold molar excess of carnitine for 1 wk. Patients in group C were treated chronically with valproic acid and received a molar equivalent (to valproic acid) of carnitine for 14 d. Patients in group A had markedly increased (16-fold) urinary carnitine ester excretion concomitant with diminished urinary free carnitine and γ-butyrobetaine output and lower plasma free carnitine concentration. Supplementation with one molar equivalent of carnitine (to pivampicillin) was ineffective in preventing the reduction of plasma carnitine concentration observed with pivampicillin treatment alone. For group B patients, administration of excess carnitine resulted in a further increase (35-fold) of urinary carnitine ester output with no decrease of plasma carnitine concentration, urinary γ-butyrobetaine, or free carnitine excretion. For patients in group C, the initially low plasma free and total carnitine concentrations and urinary output of carnitine and carnitine esters markedly increased with carnitine supplementation, but urinary excretion of γ-butyrobetaine remained unchanged. The plasma concentrations and urinary output of L-lysine and ε-N-trimethyllysine remained unchanged within each group before and after treatment. A positive linear correlation was found between urinary ε-N-trimethyllysine and 3-methylhistidine output, indicating that the rate of ε-N-trimethyllysine excretion correlates with the amount of 3-methylhistidine liberated by protein turnover. The data indicate that generation of ε-N-trimethyllysine probably depends on protein breakdown but its use for carnitine synthesis is not necessarily regulated by carnitine status.

AB - Plasma concentrations and rates of urinary excretion of carnitine and some of its precursors were studied in three groups of children receiving drugs known to cause carnitine depletion. Patients in group A received pivampicillin and a molar equivalent of carnitine for 7 d. Patients in group B received pivampicillin with a 5.8-fold molar excess of carnitine for 1 wk. Patients in group C were treated chronically with valproic acid and received a molar equivalent (to valproic acid) of carnitine for 14 d. Patients in group A had markedly increased (16-fold) urinary carnitine ester excretion concomitant with diminished urinary free carnitine and γ-butyrobetaine output and lower plasma free carnitine concentration. Supplementation with one molar equivalent of carnitine (to pivampicillin) was ineffective in preventing the reduction of plasma carnitine concentration observed with pivampicillin treatment alone. For group B patients, administration of excess carnitine resulted in a further increase (35-fold) of urinary carnitine ester output with no decrease of plasma carnitine concentration, urinary γ-butyrobetaine, or free carnitine excretion. For patients in group C, the initially low plasma free and total carnitine concentrations and urinary output of carnitine and carnitine esters markedly increased with carnitine supplementation, but urinary excretion of γ-butyrobetaine remained unchanged. The plasma concentrations and urinary output of L-lysine and ε-N-trimethyllysine remained unchanged within each group before and after treatment. A positive linear correlation was found between urinary ε-N-trimethyllysine and 3-methylhistidine output, indicating that the rate of ε-N-trimethyllysine excretion correlates with the amount of 3-methylhistidine liberated by protein turnover. The data indicate that generation of ε-N-trimethyllysine probably depends on protein breakdown but its use for carnitine synthesis is not necessarily regulated by carnitine status.

UR - http://www.scopus.com/inward/record.url?scp=0027374308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027374308&partnerID=8YFLogxK

M3 - Article

C2 - 8255678

AN - SCOPUS:0027374308

VL - 34

SP - 460

EP - 464

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 4

ER -